{
    "clinical_study": {
        "@rank": "136438", 
        "arm_group": [
            {
                "arm_group_label": "Ampligen", 
                "arm_group_type": "Experimental", 
                "description": "Ampligen (polyI-polyC12U) 200-400 mg IV infusions given twice weekly for 24 weeks"
            }, 
            {
                "arm_group_label": "No Ampligen", 
                "arm_group_type": "No Intervention", 
                "description": "No Ampligen administered for first 24 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "This is an open-label, prospective, randomized, controlled study of the safety and efficacy\n      including clinical, immunologic, and virologic assessments of adding Ampligen to \"HAART\" in\n      HIV infected patients with CD4 counts >300 and HIV-1 plasma RNA >500 and <30,000 copies/ml\n      (PCR)."
        }, 
        "brief_title": "Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART", 
        "completion_date": {
            "#text": "September 2005", 
            "@type": "Actual"
        }, 
        "condition": [
            "HIV Seropositivity", 
            "HIV Infection"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "HIV Seropositivity"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "1. Adults at least 18 years of age.\n\n          2. CD4 cell count of >300 cells.\n\n          3. HIV-1 plasma RNA >500 and <30,000 copies/ml.\n\n             A qualifying (\"screening\") HIV-1 RNA level >500 and <30,000 copies/ml must be\n             documented at least once within 40 days prior to starting Baseline while patient is\n             receiving a HAART regimen containing at least two of the following  antiretroviral\n             drugs:\n\n               -  Abacavir (Ziagen)\n\n               -  Zidovudine (Retrovir) AZT\n\n               -  Zalcitabine (Hivid) ddC\n\n               -  Didanosine (Videx) ddI\n\n               -  Stavudine (Zerit) d4T\n\n               -  Efavirenz (Sustiva)\n\n               -  Indinavir (Crixivan)\n\n               -  Ritonavir (Norvir)\n\n               -  Nelfinavir (Viracept)\n\n               -  Amprenavir (Agenerase)\n\n             The patient must have been taking this HAART regimen for four months or longer at the\n             time of the qualifying HIV-1 RNA determination.\n\n          4. History of prior treatment (including the current HAART regimen) with at least one\n             protease inhibitor (PI) and at least two nucleoside reverse transcriptase inhibitors\n             (NRTI) and/or at least one  non-nucleoside reverse transcriptase inhibitor (NNRTI)\n             and at least two nucleoside reverse transcriptase inhibitors (NRTI).\n\n          5. Karnofsky performance status of at least 70.\n\n          6. The following laboratory parameters within 14 days prior to treatment:\n\n               -  Hemoglobin > 9.2 g/dL for men and > 8.9 g/dL for women\n\n               -  Neutrophil count > 1000\n\n               -  Platelet count > 75,000\n\n               -  AST/ALT < 4.0 x upper limit of normal (ULN)\n\n               -  Serum creatinine < 1.5 x ULN or a  creatinine clearance > 50 mL/min.\n\n          7. For females with child bearing potential: A negative serum pregnancy test within 14\n             days prior to randomization.  Males and females of child bearing potential agree to\n             use an effective means of contraception."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 3, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00035581", 
            "org_study_id": "AMP 719"
        }, 
        "intervention": {
            "arm_group_label": "Ampligen", 
            "description": "200-400 mg IV infusions 2x/week for 24 weeks", 
            "intervention_name": "poly I-poly C12U", 
            "intervention_type": "Drug", 
            "other_name": [
                "Ampligen", 
                "Rintatolimod"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Poly I-C", 
                "Ampligen"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "treatment experienced", 
            "HIV Infections", 
            "HIV", 
            "HAART", 
            "early virologic failure"
        ], 
        "lastchanged_date": "April 16, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Fountain Valley", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92708"
                    }, 
                    "name": "Orange County Center for Special Immunology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Norwalk", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06851"
                    }, 
                    "name": "Circle Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20009"
                    }, 
                    "name": "Dupont Circle Physicians Group"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Lauderdale", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33306"
                    }, 
                    "name": "Julia Torres, MD"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33607"
                    }, 
                    "name": "Scott Ubillos, MD"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newark", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07102"
                    }, 
                    "name": "St. Michael's Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Reading", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19601"
                    }, 
                    "name": "W. Chris Woodward, DO"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multi-Center, Randomized, Controlled Study of the Biological Actions of Ampligen as an Adjunct to HAART in HIV Disease", 
        "overall_official": {
            "affiliation": "Hemispherx Biopharma", 
            "last_name": "David R Strayer, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2005", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Evaluate the effects of adding Ampligen (or no Ampligen) to \"HAART\" in HIV+ patients for evidence of reductions in HIV-1 viral load in plasma using Roche Amplicor assay.", 
            "measure": "Reduction in HIV-1 Viral Load", 
            "safety_issue": "No", 
            "time_frame": "4, 8, 12, 16, 20 and 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00035581"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Hemispherx Biopharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hemispherx Biopharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2001", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }, 
    "geocoordinates": {
        "Circle Medical Center": "41.118 -73.408", 
        "Dupont Circle Physicians Group": "38.895 -77.036", 
        "Julia Torres, MD": "26.122 -80.143", 
        "Orange County Center for Special Immunology": "33.709 -117.954", 
        "Scott Ubillos, MD": "27.951 -82.457", 
        "St. Michael's Medical Center": "40.736 -74.172", 
        "W. Chris Woodward, DO": "40.336 -75.927"
    }
}